Updates are available Correction dated 2021-10-21

Article History

Accepted: 20 August 2021

First Online: 29 September 2021

Change Date: 21 October 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40265-021-01622-x

Declarations

:

: This study was funded by GlaxoSmithKline (study number 213172).

: CDR has received funding for travel or speaker fees from ALK, Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, Novartis, Stallergenes and Pfizer. TCD has received speaker fees from ALK, Diater, GSK, LETI and Novartis. MBA has received speaker or consulting fees from ALK, AstraZeneca, Chiesi, GSK, Novartis, Teva and Zambón. EMM has received speaker or consulting fees from ALK, AstraZeneca, BIAL, Boehringer Ingelheim, Chiesi, GSK, Novartis, Teva, and Sanofi. DBC and MGSH are employees of GSK. CDR, TCD, MBA and EMM declare no specific conflicts of interest to report regarding this paper.

: This study was performed in line with the principles of the Declaration of Helsinki and order SAS/3470/2009. Approval was granted by the Ethics Committee of Hospital La Princesa, Madrid, on 25 September 2019.

: Informed consent was obtained from all individual participants included in the study.

: Informed consent obtained included the publication of participants’ aggregate and anonymized health data.

: Not applicable.

: Not applicable.

: CDR, DBC, MGSH, TCD, MBA, EMM reviewed the literature and critically edited the manuscript. All authors read and approved the final version of the manuscript.